175 related articles for article (PubMed ID: 35043946)
1. Population-Based Newborn Screening for Germline TP53 Variants: Clinical Benefits, Cost-Effectiveness, and Value of Further Research.
Kunst N; Stout NK; O'Brien G; Christensen KD; McMahon PM; Wu AC; Diller LR; Yeh JM
J Natl Cancer Inst; 2022 May; 114(5):722-731. PubMed ID: 35043946
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of early cancer surveillance for patients with Li-Fraumeni syndrome.
Tak CR; Biltaji E; Kohlmann W; Maese L; Hainaut P; Villani A; Malkin D; Sherwin CMT; Brixner DI; Schiffman JD
Pediatr Blood Cancer; 2019 May; 66(5):e27629. PubMed ID: 30719841
[TBL] [Abstract][Full Text] [Related]
3. Cancer incidence, patterns, and genotype-phenotype associations in individuals with pathogenic or likely pathogenic germline TP53 variants: an observational cohort study.
de Andrade KC; Khincha PP; Hatton JN; Frone MN; Wegman-Ostrosky T; Mai PL; Best AF; Savage SA
Lancet Oncol; 2021 Dec; 22(12):1787-1798. PubMed ID: 34780712
[TBL] [Abstract][Full Text] [Related]
4. Universal newborn genetic screening for pediatric cancer predisposition syndromes: model-based insights.
Yeh JM; Stout NK; Chaudhry A; Christensen KD; Gooch M; McMahon PM; O'Brien G; Rehman N; Blout Zawatsky CL; Green RC; Lu CY; Rehm HL; Williams MS; Diller L; Wu AC
Genet Med; 2021 Jul; 23(7):1366-1371. PubMed ID: 33767345
[TBL] [Abstract][Full Text] [Related]
5. Genome-first approach of the prevalence and cancer phenotypes of pathogenic or likely pathogenic germline TP53 variants.
de Andrade KC; Strande NT; Kim J; Haley JS; Hatton JN; Frone MN; Khincha PP; Thone GM; Mirshahi UL; Schneider C; Desai H; Dove JT; Smelser DT; ; ; Levine AJ; Maxwell KN; Stewart DR; Carey DJ; Savage SA
HGG Adv; 2024 Jan; 5(1):100242. PubMed ID: 37777824
[TBL] [Abstract][Full Text] [Related]
6. Evolution of germline TP53 variant classification in children with cancer.
Tallis E; Scollon S; Ritter DI; Plon SE
Cancer Genet; 2022 Jun; 264-265():29-32. PubMed ID: 35306447
[TBL] [Abstract][Full Text] [Related]
7. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: 11 year follow-up of a prospective observational study.
Villani A; Shore A; Wasserman JD; Stephens D; Kim RH; Druker H; Gallinger B; Naumer A; Kohlmann W; Novokmet A; Tabori U; Tijerin M; Greer ML; Finlay JL; Schiffman JD; Malkin D
Lancet Oncol; 2016 Sep; 17(9):1295-305. PubMed ID: 27501770
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of TP53 germline variants and their correlations with Li-Fraumeni syndrome or Li-Fraumeni-like syndrome in Chinese tumor patients.
Tian P; Zhang X; Yang S; Fang Y; Yuan H; Li W; Zhu H; Zhao F; Ding J; Zhu Y; Wang S; Sun G; Ni H; Ma T; Lei T
J Genet Genomics; 2022 Jul; 49(7):645-653. PubMed ID: 35033608
[TBL] [Abstract][Full Text] [Related]
9. Analysis of the Li-Fraumeni Spectrum Based on an International Germline TP53 Variant Data Set: An International Agency for Research on Cancer TP53 Database Analysis.
Kratz CP; Freycon C; Maxwell KN; Nichols KE; Schiffman JD; Evans DG; Achatz MI; Savage SA; Weitzel JN; Garber JE; Hainaut P; Malkin D
JAMA Oncol; 2021 Dec; 7(12):1800-1805. PubMed ID: 34709361
[TBL] [Abstract][Full Text] [Related]
10. Medical guidelines for Li-Fraumeni syndrome 2019, version 1.1.
Kumamoto T; Yamazaki F; Nakano Y; Tamura C; Tashiro S; Hattori H; Nakagawara A; Tsunematsu Y
Int J Clin Oncol; 2021 Dec; 26(12):2161-2178. PubMed ID: 34633580
[TBL] [Abstract][Full Text] [Related]
11. Clinical spectrum of Li-Fraumeni syndrome/Li-Fraumeni-like syndrome in Brazilian individuals with the TP53 p.R337H mutation.
Ferreira AM; Brondani VB; Helena VP; Charchar HLS; Zerbini MCN; Leite LAS; Hoff AO; Latronico AC; Mendonca BB; Diz MDPE; de Almeida MQ; Fragoso MCBV
J Steroid Biochem Mol Biol; 2019 Jun; 190():250-255. PubMed ID: 30974190
[TBL] [Abstract][Full Text] [Related]
12. Evaluation of
Schwartz AN; Hyman SR; Stokes SM; Castillo D; Tung NM; Weitzel JN; Rana HQ; Garber JE
JCO Precis Oncol; 2021 Nov; 5():1677-1686. PubMed ID: 34994652
[TBL] [Abstract][Full Text] [Related]
13. Risks of first and subsequent cancers among TP53 mutation carriers in the National Cancer Institute Li-Fraumeni syndrome cohort.
Mai PL; Best AF; Peters JA; DeCastro RM; Khincha PP; Loud JT; Bremer RC; Rosenberg PS; Savage SA
Cancer; 2016 Dec; 122(23):3673-3681. PubMed ID: 27496084
[TBL] [Abstract][Full Text] [Related]
14. Whole body magnetic resonance imaging (WB-MRI) and brain MRI baseline surveillance in TP53 germline mutation carriers: experience from the Li-Fraumeni Syndrome Education and Early Detection (LEAD) clinic.
Bojadzieva J; Amini B; Day SF; Jackson TL; Thomas PS; Willis BJ; Throckmorton WR; Daw NC; Bevers TB; Strong LC
Fam Cancer; 2018 Apr; 17(2):287-294. PubMed ID: 28988289
[TBL] [Abstract][Full Text] [Related]
15.
Terradas M; Mur P; Belhadj S; Woodward ER; Burghel GJ; Munoz-Torres PM; Quintana I; Navarro M; Brunet J; Lazaro C; Pineda M; Moreno V; Capella G; Evans DGR; Valle L
Gut; 2021 Jun; 70(6):1139-1146. PubMed ID: 32998877
[TBL] [Abstract][Full Text] [Related]
16. Biochemical and imaging surveillance in germline TP53 mutation carriers with Li-Fraumeni syndrome: a prospective observational study.
Villani A; Tabori U; Schiffman J; Shlien A; Beyene J; Druker H; Novokmet A; Finlay J; Malkin D
Lancet Oncol; 2011 Jun; 12(6):559-67. PubMed ID: 21601526
[TBL] [Abstract][Full Text] [Related]
17. Prevalence of Cancer at Baseline Screening in the National Cancer Institute Li-Fraumeni Syndrome Cohort.
Mai PL; Khincha PP; Loud JT; DeCastro RM; Bremer RC; Peters JA; Liu CY; Bluemke DA; Malayeri AA; Savage SA
JAMA Oncol; 2017 Dec; 3(12):1640-1645. PubMed ID: 28772286
[TBL] [Abstract][Full Text] [Related]
18. Germline TP53 Mutations in Patients With Early-Onset Colorectal Cancer in the Colon Cancer Family Registry.
Yurgelun MB; Masciari S; Joshi VA; Mercado RC; Lindor NM; Gallinger S; Hopper JL; Jenkins MA; Buchanan DD; Newcomb PA; Potter JD; Haile RW; Kucherlapati R; Syngal S;
JAMA Oncol; 2015 May; 1(2):214-21. PubMed ID: 26086041
[TBL] [Abstract][Full Text] [Related]
19. Guidelines for the Li-Fraumeni and heritable TP53-related cancer syndromes.
Frebourg T; Bajalica Lagercrantz S; Oliveira C; Magenheim R; Evans DG;
Eur J Hum Genet; 2020 Oct; 28(10):1379-1386. PubMed ID: 32457520
[TBL] [Abstract][Full Text] [Related]
20. Utility of interim blood tests for cancer screening in Li-Fraumeni syndrome.
Oba L; Best AF; Mai PL; Achatz MI; Albert PS; Savage SA; Khincha PP
Fam Cancer; 2022 Jul; 21(3):333-336. PubMed ID: 34076823
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
